ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: Grand Jury To Consider Charges Against N.M. Community Based Cancer Program Staff Members

January 4, 1980

Combine Phase 1-2, Abolish DRG, Slash Indirect Costs, Garb Tells Congress

November 27, 1981

NCI’s Kramer Named Director, NIH Medical Applications Office.

June 16, 2000

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

Final stats On FY92 Budget; Success Rate Was 35 Percent

December 4, 1992

Drug Shortages: Institutions Report Halting Enrollment in Clinical Trials

March 22, 2013